CBD for Urinary Incontinence

Recruiting in Palo Alto (17 mi)

Overseen byJavi Santiago

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: University of Wisconsin, Madison

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The goal of this feasibility study is to learn whether Cannabidiol (CBD) can improve urinary incontinence and other symptoms in people with recent spinal cord injury (SCI). Participants will take Epidiolex (purified CBD) for 90 days

Eligibility Criteria

This trial is for English-speaking adults over 18 with recent supra-sacral spinal cord injury causing urinary incontinence of at least two episodes per day. Participants must be willing to try a drug intervention but not use any cannabis outside the study or have certain mood disorders, and can't be on high doses of specific bladder medications.

Inclusion Criteria

Willingness to participate in drug intervention trial

English-speaking (able to provide consent and complete questionnaires)

I am older than 18 years.

See 2 more

Exclusion Criteria

Use of Cannabis (any form) outside of study as determined by urine drug screen after washout period of 1 month if prior Cannabis use reported

Presence of thought or mood disorder aside from depression

I am taking more than 15 mg of Oxybutynin or a similar medication for bladder issues.

See 1 more

Treatment Details

Interventions

Cannabidiol (Cannabinoid)

Trial OverviewThe study tests if Cannabidiol (CBD), specifically Epidiolex, can help manage urinary incontinence and related symptoms in people with spinal cord injuries. Participants will take purified CBD for a duration of 90 days to assess its effectiveness.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: CBD for urinary incontinenceExperimental Treatment1 Intervention

Participants will take CBD for 90 days